Gland Pharma Gets USFDA Nod for Zoledronic Acid Injection for Cancer-Related Bone Disorders

Published On 2026-02-07 15:15 GMT | Update On 2026-02-07 15:15 GMT

Hyderabad: Gland Pharma Limited, a generic injectable and ophthalmic-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/mL) single-dose bags.

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/mL), marketed by Info RLife. The injection is indicated for the treatment of hypercalcemia of malignancy, multiple myeloma, and bone metastases arising from solid tumors.

According to IQVIA data, Zoledronic Acid Injection recorded sales of approximately USD 6.7 million in the United States for the twelve-month period ending November 2025, indicating a modest but stable market opportunity for the product.

Also Read: Gland Pharma Gets USFDA Approval for Olopatadine Ophthalmic Solution

With this approval, Gland Pharma continues to strengthen its injectable portfolio in the US market, reinforcing its focus on complex sterile injectables and oncology-related therapies.

Established in 1978 and headquartered in Hyderabad, Gland Pharma operates primarily under a business-to-business (B2B) model and has built a strong global presence across over 60 countries, including the United States, Europe, Canada, Australia, and India. The company has a proven track record in developing and manufacturing sterile injectables across multiple dosage forms such as vials, ampoules, pre-filled syringes, lyophilized products, infusions, oncology injectables, and ophthalmic solutions. It is also recognised for pioneering heparin technology in India.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

sheeba farhat

Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Gland Pharma Gets USFDA Nod for Zoledronic Acid Injection for Cancer-Related Bone Disorders

Similar News

Sigachi Pharma CEO Gets Conditional Bail in Sangareddy Blast Case That Killed 54 Workers

Fake Liv 52, Ibugesic Plus, Cosglo Cream Seized as Bihar DCA Busts Illegal Drug Unit

Pharmacy Store Owner to Be Booked for Abetment After 20-Year-Old Attendant Found Dead in Pune

Sun Pharma Rules Out Big-Bang Acquisitions, Bets on Organic Growth and Biosimilars

Fire at Emcure Pharma's Pune Plant, Operations Temporarily Halted

Alembic Pharma Q3 FY26 Profit Slips to Rs 133 Cr After One-Time Labour Code Provision, Revenue Up 11%

Pharma Firms May Need Prior Approval for Major Drug Changes Under NDCT Draft Amendment

Aurobindo Pharma Gets 11 USFDA Observations at Eugia Unit